Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA WILL DENY SCHERING’s PETITION AGAINST ANDAs FOR NON-SYSTEMICALLY

Executive Summary

FDA WILL DENY SCHERING's PETITION AGAINST ANDAs FOR NON-SYSTEMICALLY absorbed drug products, FDA Associate Chief Counsel for Drugs David Adams told a Food and Drug Law Institute conference June 19 in Brussels, Belgium. "The agency is going to deny that petition and that issue will probably be resolved in court," Adams predicted. Schering maintained in the petition, filed late last year ("The Pink Sheet" Dec. 11, T&G-12), that "the statutory requirement of bioequivalence cannot be satisfied" for nonabsorbable products and, therefore, ANDAs based on bioequivalence should not be accepted. Adams indicated that the Waxman/Hatch Act "does not on its face mean that [blood level studies are] the only way. The statute does not necessarily have to be read as [blood level studies] being exclusive to showing bioequivalence." He asserted that bioequivalence could be shown through other means such as in vitro studies, dissolution studies and skin blanching tests. At the meeting, attorney Paul Hyman (D.C. law firm of Hyman, Phelps & McNamara) suggested that "nothing in the statute or legislative history...makes it clear what the answer should be." Adams responded: "It is extremely unlikely that Congress intended by writing the statute this way to stop FDA's approval of topical products."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS017658

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel